NCT04169074 2026-01-14
Immune Modulation by Abemaciclib in Head and Neck Squamous Cell Carcinoma (HNSCC). (AIM Trial)
University of Arizona
Phase 2 Terminated
Clinical Trials
12 trialsNCT03935893 2025-07-10
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
University of Pittsburgh
Phase 2 Recruiting
NCT00076310 2025-06-26
OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04357873 2025-02-19
PEVOsq
UNICANCER
Phase 2 Completed
NCT05761132 2023-03-09
Apollo
Leiden University Medical Center
Phase 2 Unknown
NCT05252078 2022-12-16
ALTER-E005
Jiangxi Provincial Cancer Hospital
Phase 2 Recruiting
NCT02837042 2022-06-21
Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma
University of Alabama at Birmingham
Phase 2 Terminated
NCT04435938 2020-12-02
SHINE
McMaster University
Phase 2 Unknown
NCT01111058 2020-04-07
Everolimus Versus Placebo in Head and Neck Cancer
University of Chicago
Phase 2 Terminated
NCT01581970 2019-09-11
Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT00661427 2018-01-11
Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00591149 2017-06-14
Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer
University of Kansas Medical Center
Phase 2 Terminated